Canadian Research Network for Adult Congenital Heart Disease Interventions (CRN-ACHDi)

Established in 2019, the CRN-ACHDi brings together 15 clinical experts and researchers from five provinces (AB, BC, MB, ON, QC) and eight centers. The Canadian Congenital Heart Alliance (CCHA) is our patient partner organization. We started the first RCT in the world that will compare three devices for transcatheter closure of atrial septal defects (Trio ASD, NCT04291898), initiated a study to evaluate the effect of patent foramen ovale on the risk of perioperative stroke (CAPPRES, NCT05592301), and are now designing i) an RCT to evaluate the effectiveness of patent foramen closure in elderly, and ii) a platform trial to evaluate novel device therapies for pulmonary valve implantation patients with Tetralogy of Fallot. Our prospective registry of adult congenital heart disease interventions (C-ACHDiR, NCT04288596) now incorporates patient-reported outcomes and experiences. The Network fosters a strong collaborative and multidisciplinary research environment to promote multisite, high-quality studies in this rare population.

The Accelerating Clinical Trials Consortium is generously supported through multi-year funding from the Canadian Institutes of Health Research’s Clinical Trials Fund, as part of Canada’s Biomanufacturing and Life Sciences Strategy to ensure that Canadians are well served by a national clinical trials network.